Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Monconduit

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1991
Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma GroupP Carde, J H Meerwaldt, M van Glabbeke, et al.
British Journal of Haematology|February 1, 1992
VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myélome (GERM)M Monconduit, J F Menard, J L Michaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1988
Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factorsP Carde, J M Burgers, M Henry-Amar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myelomaP Moreau, D Fiere, W R Bezwoda, et al.
British Journal of Haematology|December 1, 1996
Soluble CD16 (sCD16), a marker of malignancy in individuals with monoclonal gammopathy of undetermined significance (MGUS)C Mathiot, J Y Mary, E Tartour, et al.
Leukemia & Lymphoma|March 28, 1998
PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des LeucémiesB Lenormand, M C Béné, J F Lesesve, et al.
Cancer|July 1, 1981
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysisJ L Binet, A Auquier, G Dighiero, et al.
British Journal of Haematology|November 25, 1998
VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85)P Mineur, J F Ménard, X Le Loët, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1991
Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma GroupP Carde, J H Meerwaldt, M van Glabbeke, et al.
British Journal of Haematology|February 1, 1992
VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myélome (GERM)M Monconduit, J F Menard, J L Michaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1988
Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factorsP Carde, J M Burgers, M Henry-Amar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myelomaP Moreau, D Fiere, W R Bezwoda, et al.
British Journal of Haematology|December 1, 1996
Soluble CD16 (sCD16), a marker of malignancy in individuals with monoclonal gammopathy of undetermined significance (MGUS)C Mathiot, J Y Mary, E Tartour, et al.
Leukemia & Lymphoma|March 28, 1998
PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des LeucémiesB Lenormand, M C Béné, J F Lesesve, et al.
Cancer|July 1, 1981
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysisJ L Binet, A Auquier, G Dighiero, et al.
British Journal of Haematology|November 25, 1998
VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85)P Mineur, J F Ménard, X Le Loët, et al.
Pageof 8